Aktuellt
SENASTE
Isofol Medical today announced it has entered into a licencing agreement with Solasia Pharma for the development and commercialisation of its main asset arfolitixorin in Japan. It will receive cUSD100m in upfront and sales-related payments, with additional double-digit royalties. We view today’s announcement as an important commercial milestone and believe it speaks favourably about management’s ability to deliver despite difficulties relating to Covid-19. We have updated our out-licencing scenario and increased the share count; we have raised our fair value to SEK10–23 (8–22).
LÄS MER
